Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006219 · ClinicalTrials.gov registry record · Phase 2
Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006219: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00006219 is a Phase 2 study that has completed, run by Mayo Clinic. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006219, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.
Interventions
- DRUG prasterone
- DRUG clarithromycin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
What the finished NCT00006219 record still lists
NCT00006219 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which prasterone is the first listed.
NCT00006219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006219 about?
NCT00006219 is a clinical study titled "Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandroster...
What is the current status of trial NCT00006219?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-08. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00006219?
The interventions under investigation include: prasterone (DRUG), clarithromycin (DRUG).
Who is sponsoring clinical trial NCT00006219?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia